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Abstract 
Background: Scedosporium apiospermum is an emerging opportunistic filamentous fungus, which is notorious for its 
high levels of antifungal‑resistance. It is able to cause localized cutaneous or subcutaneous infections in both immu‑
nocompromised and immunocompetent persons, pulmonary infections in patients with predisposing pulmonary 
diseases and invasive mycoses in immunocompromised patients. Subcutaneous infections caused by this fungus 
frequently show chronic mycetomatous manifestation.
Case report: We report the case of a 70‑year‑old immunocompromised man, who developed a fungal mycetoma‑
tous infection on his right leg. There was no history of trauma; the aetiological agent was identified by microscopic 
examination and ITS sequencing. This is the second reported case of S. apiospermum subcutaneous infections in 
Hungary, which was successfully treated by surgical excision and terbinafine treatment. After 7 months, the patient 
remained asymptomatic. Considering the antifungal susceptibility and increasing incidence of the fungus, Sce-
dosporium related subcutaneous infections reported in the past quarter of century in European countries were also 
reviewed.
Conclusions: Corticosteroid treatment represents a serious risk factor of S. apiospermum infections, especially if the 
patient get in touch with manure‑enriched or polluted soil or water. Such infections have emerged several times in 
European countries in the past decades. The presented data suggest that besides the commonly applied voricona‑
zole, terbinafine may be an alternative for the therapy of mycetomatous Scedosporium infections.
Keywords: Filamentous fungi, Cutaneous infection, Antifungal susceptibility, Immunosuppression, Corticosteroid 
therapy, Scedosporium apiospermum
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Background
Scedosporium apiospermum is a ubiquitous, saprophytic 
filamentous fungus, which can be isolated mainly from 
environments affected by human activity (i.e. manure-
enriched or polluted soils and water) [1]. It is an emerg-
ing opportunist that can cause trauma-associated, 
localized infections, colonization of pulmonary cavities 
in patients with predisposing pulmonary disorders (such 
as cystic fibrosis) and systemic invasive diseases in immu-
nocompromised patients [2]. This mould is notorious for 
its therapy-refractory nature and resistance for several 
antifungal agents [1, 3]. Traumatic localized infections 
can occur in both immunocompromised and immuno-
competent persons and are most frequently manifested 
as mycetomatous, chronic progressive subcutaneous 
infections, which may also reach the muscles and the 
bones [1]. Scedosporium-caused mycetomas can be found 
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worldwide but most cases have been reported in western 
Europe, Australia and North America [4–6]. Here, we 
report a Hungarian patient with recurrent mycetomatous 
S. apiospermum infection successfully treated by surgical 
excision and terbinafine treatment and review the similar 
cases reported during the past 2 decades in Europe.
Case presentation
A 70-year-old man, who worked at a vegetable plantation 
in previous years, was admitted to our institution with 
severe edema on the lower right leg and foot, accom-
panied by pain, fever (38.3  °C), erythema, numerous 
small-sized papules and abscesses. There was no medi-
cal history of notable trauma, however the patient did 
undergo a prosthesis implantation surgery of the right 
knee, 10 years ago.
In the previous year, he was hospitalized because of 
melena and anemia. The patient was given 8 units of red 
blood cell transfusions and underwent gastroscopy, colo-
noscopy and abdominal computed tomography angi-
ography. Comprehensive gastrointestinal examination 
found no source of bleeding, however, laboratory tests 
showed significant proteinuria (10  g/day), low albumin 
(22  g/L) and IgG (5.24  g/L) levels. A kidney biopsy was 
performed, which revealed focal segmental glomerulo-
sclerosis. Owing to the possibility of myeloma multiplex 
and amyloidosis, additional tests were also carried out 
with negative results. Based on these findings, the patient 
was diagnosed with nephrotic syndrome and received 
corticosteroid pulse therapy (3 × 750 mg) intravenously, 
which was then switched to oral administration. In the 
following weeks, the corticosteroid dose was gradually 
reduced from 80 to 16–8 mg, without any complications.
Three months later, he developed fever (38.3 °C), swell-
ing and erythema on both legs. In addition, small pete-
chiae could also be observed on his arms, torso and right 
knee, which was interpreted as vasculitis caused by  the 
patient’s septic state. Laboratory results displayed pro-
foundly high C-reactive protein (CRP; 354.9 mg/L) level 
and erythrocyte sedimentation rate (94 mm/h). Based on 
the clinical symptoms, erysipelas and sepsis were consid-
ered to be the initial diagnoses and the patient was put 
on a course of antibiotic treatment (3 × 1.2 g amoxicil-
lin and clavulanic acid). After 4 days, subsequent labora-
tory values for CRP and erythrocyte sedimentation rate 
showed 76.8 mg/L and 84 mm/h, respectively.
After 2  weeks, however, the patient was referred to 
our clinic, owing to the progression in his cutaneous 
symptoms. The patient then presented with a severely 
oedemic and painful lower right leg, with slight erythema 
and multiple small soft papules (Fig. 1). In addition, the 
whole skin of this extremity had a sponge-like feel to the 
touch. No notable symptoms were present on the left leg. 
Laboratory tests showed elevated CRP (38  mg/L) and 
high white blood cell count (12.85 × 109/L). Ultrasound 
revealed four 10–13 mm-sized subcutaneous collections 
of echogenic fluid in the right leg. After incision and 
drainage of these lesions, swabs were sent to the micro-
biological laboratory for culturing. Only Scedosporium 
apiospermum grew in culture after 3 days of incubation 
at normal atmosphere at 30  °C. After accurate morpho-
logical assessment, the sample was sent for additional 
identification by DNA sequencing.
Considering this finding, instead of the initially admin-
istered penicillin-type antibiotic, the patient was given 
fluconazole (200  mg) intravenously on six occasions, 
to which his symptoms markedly improved. Subse-
quently, taking the patient’s low glomerular filtration rate 
(56 mL/min) into account, he was prescribed a synthetic 
allylamine antifungal medication (250 mg terbinafine) to 
take every second day with the aim of minimizing poten-
tial side effects and underwent several other abscess 
Fig. 1 Edema, erythema and small superficial abscesses (white 
arrows) on the lower right leg and foot
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drainages in the following weeks, in addition to the local 
antimicrobial agents (i.e. betadine, hydrogen peroxide, 
and boric acid powder). Parallel with his treatment for 
the mycotic infection, his steroid therapy dose was grad-
ually decreased and his nephrotic syndrome improved. 
Two months into his treatment, he experienced a recur-
rent infection on the right leg. At this time, no mycotic 
infection could be proven, as only Staphylococcus aureus 
was cultured from multiple small superficial abscesses, 
thus the patient received a combination antibiotic of 
piperacillin and tazobactam (3 ×  4.5  g) for a week, fol-
lowed by amoxicillin and clavulanic acid (4 × 1.2 g) for 
another week, to which his symptoms regressed.
Though edema of the right leg persisted even after 
many months, there were no longer any clinical signs 
of inflammation and the patient did not experience any 
pain. Leukocyte scintigraphy displayed increased activity 
around the right ankle, suggesting the development of a 
new abscess, but it was successfully managed with anti-
biotic and local treatment. After 7  months, the patient 
remained asymptomatic and currently maintains a low 
dose of corticosteroid (4  mg/day) therapy. In addition 
to occupational exposure, low serum IgG levels and the 
immunosuppressive effect of the corticosteroid treat-
ment were most likely compelling factors in further sub-
stantiating the likelihood of this rare fungal infection in 
our patient’s case.
Mycological investigations
The isolate was deposited in the Szeged Microbiology 
Collection (SZMC; http://www.wfcc.info/ccinfo/collec-
tion/by_id/987) with the strain number SZMC 23374 
and was sub-cultured on malt extract agar (MEA; 5% 
malt extract, 1% glucose, 2% agar) plates at 37  °C for 
further morphological and molecular examinations. It 
formed greyish–white, cotton-like colonies on MEA 
(Fig.  2a). Microscopic examination revealed branched 
hyphae with clavate or ovoid conidia born singly on sim-
ple or branched conidiophores or laterally on the hyphae 
(Fig. 2b).
For molecular identification, genomic DNA was 
extracted from 10 mg of mycelium ground to a fine pow-
der in liquid nitrogen and purified by using the Mas-
terPure Yeast DNA purification kit (Epicentre, USA) 
according to the instructions of the manufacturer. The 
complete ITS (internal transcribed spacer, including 
ITS1-5.8S rRNA-ITS2) region was amplified by PCR, 
using the primers ITS1 and ITS4 [7]. The resulting ampli-
cons were sequenced at LGC Genomics (Germany). 
The determined sequence was deposited in the Euro-
pean Nucleotide Archive (ENA, http://www.ebi.ac.uk/
ena) database (Accession number: LT703449) and used 
for similarity searches in the NCBI database using the 
BLASTN algorithm (http://blast.ncbi.nlm.nih.gov/Blast.
cgi), which confirmed the fungus as S. apiospermum 
(identities for the whole ITS region, 99%).
In vitro susceptibility of the S. apiospermum isolate to 
amphotericin B (AMB), fluconazole (FLC), itraconazole 
(ITC), voriconazole (VRC), caspofungin (CSP), natamy-
cin (NTM) and terbinafine (TRB) (Sigma-Aldrich, USA) 
was tested using the broth microdilution method accord-
ing to the CLSI guideline M38-A2 [8]. Minimal inhibitory 
concentration (MIC) values were determined in 96-well 
microtiter plates by visual inspection of the cultures after 
72 h incubation at 37 °C in standard RPMI-1640 medium 
(Sigma-Aldrich, USA). Inocula were prepared from 
14-day cultures grown on MEA; the final conidial sus-
pensions contained 104 CFU/mL. Final concentrations of 
the drugs ranged from 0.5 to 256 μg/mL. Each plate con-
tained a sterile control (containing medium alone) and a 
growth control (containing inoculated medium without 
the drugs). Each experiment was performed in triplicates; 
Fig. 2 Colony (a) and micromorphology (b) of Scedosporium apiospermum isolate SZMC 23374. Scale bar 10 µm
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Paecilomyces variotii ATCC 22319 was used as the qual-
ity control strain. Table  1 shows the antifungal suscep-
tibility of the case isolate to the most frequently used 
antifungal agents. The strain showed low susceptibility to 
AMB, CSP, ITC and TRB. FLC and NTM proved to be 
ineffective against the isolate in the investigated concen-
tration range (MIC >128 μg/mL). It was the most suscep-
tible to VRC (MIC 2 μg/mL).
Discussion
Mycetoma (syn. Madura foot) is the infection of the skin 
and subcutaneous tissues, which usually develops after 
a traumatic event of the leg or the foot. It is endemic in 
tropical and subtropical countries, but rarely reported 
from temperate regions, as well. Based on the causative 
agents, the disease can be divided into two categories: 
actinomycetoma or actinomycosis is caused by Actino-
mycetes, while eumycetoma or maduramycosis is caused 
by filamentous fungi [2].
Scedosporium apiospermum was first isolated in 1909 
as the aetiological agent of a white grain mycetoma in 
Sardinia by Tarozzi [9, 10]. This species was considered 
to be the anamorph of Scedosporium boydii (previously 
known as Pseudallescheria boydii) until 2005, when they 
proved to be two distinct species based on molecular, 
physiological and biochemical data [11]. According to the 
latest molecular studies S. apiospermum is a species com-
plex, comprising five distinct species: S. apiospermum, 
Scedosporium aurantiacum, S. boydii, Scedosporium 
minutisporum, and Scedosporium dehoogii. Out of them, 
S. apiospermum, S. aurantiacum and S. boydii, are regu-
larly isolated from human infections [12]. Their incidence 
seems to be increasing, especially among immunocom-
promised patients. After Aspergillus fumigatus, S. api-
ospermum and S. boydii are the second most frequently 
isolated moulds in cystic fibrosis patients [13].
Based on the available case reports in English and 
Spanish in the PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) and Google Scholar (https://scholar.google.
hu/) databases, 20 cases of mycetoma or subcutaneous 
infections were reported due to Scedosporium species 
between 1992 and 2015 from ten European countries: 
4–4 from Germany and the UK, 2–2 from The Nether-
lands, Spain, France, and Turkey and 1–1 from Italy, Ser-
bia, Slovenia, and Hungary [14–32] (Table 2; Fig. 3). Two 
additional cases have been diagnosed in France, but these 
patients arrived from outside of Europe (Ivory Coast and 
Martinique) for hospitalization [33, 34] (not included in 
Table 2). Of the 20 European cases, 15 were registered in 
immunosuppressed patients having different underlying 
conditions, such as organ transplantations, acute mye-
loid leukemia (AML) or chronic obstructive pulmonary 
disease (COPD). Similarly to the presented case, out of 
these patients, 12 had been given a corticosteroid treat-
ment. Although it was not yet proven that these drugs 
would play a role in the development of Scedosporium 
infections not just as immunosuppressants but as fungal 
growth stimulators as well, hydrocortisone has previously 
proven to enhance the growth of Aspergilli [35]. Tak-
ing into account that the patient in the present case had 
worked with manured garden soil during the corticoster-
oid therapy, characteristic preference of the fungus for 
such eutrophic and manure-enriched environments [1] 
could also represent a serious risk factor for the patient 
besides the corticosteroid treatment.
The causative agents were identified as S. apiosper-
mum and S. boydii in 15 and 7 cases, respectively. While, 
coinfections of Scedosporia and bacteria (i.e. Nocardia 
abscessus or unidentified Gram+  and Gram−  bacteria) 
were recorded in two cases [15, 30]. However, the real 
incidence of the two species is unknown, since much of 
the case reports have been published before 2005 and 
mention S. boydii and S. apiospermum as the sexual and 
asexual form of the same organism. It is also worth to 
mention that according to a recent case study of Chen 
et  al. [13], the discrimination of S. apiospermum and S. 
boydii does not result in a different therapeutic approach.
Sixteen of the cases identified in our literature review 
had positive outcome, one patient did not show up 
for follow-up examinations, while in another case, the 
infected limb has been amputated. In addition to these, 
two fatal cases have also been recorded, however they 
could not be connected to the infections caused by Sce-
dosporia. Based on the summarized literature data in 
Table  2, the most common successfully applied medi-
cal therapy involved azole antifungals, i.e. voriconazole 
or itraconazole. Reimann et  al. [16] achieved improve-
ment using miconazole combined with vacuum seal 
and suction technique. Combination antifungal therapy 
was reported in one case, when after a failed treatment 
with fluconazole and liposomal amphotericin B, the 
patient was cured successfully with the combination of 
Table 1 MIC values (μg/mL) of antifungal drugs to the S. apiospermum isolate SZMC 23374
AMB amphotericin B, CSP caspofungin, FLC fluconazole, ITC itraconazole, NTM natamycin, TRB terbinafine, VRC voriconazole
Aetiological agent MIC (µg/mL)
AMB CSP FLC ITC NTM TRB VRC
S. apiospermum 16 32 >256 32 >128 64 2
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voriconazole and caspofungin [18]. Surgical excision 
alone without antifungal therapy was applied in one case 
[28], while amputation without attempting any antifungal 
treatment was performed once in Turkey [30]. Medical 
therapy (itraconazole) plus surgery was used in the case 
reported by Montero et al. [20]. Amphotericin B has been 
applied several times, but it has always been replaced by 
other antifungals due to its toxicity or ineffectiveness. 
Based on these data, the treatment applied in the present 
case is unique in the European literature, since terbin-
afine alone or in combination with other antifungals or 
surgical intervention has not been applied successfully 
for the treatment of S. apiospermum mycetoma before. 
Although, an S. apiospermum skin infection has been 
successfully treated by terbinafine combined with vori-
conazole and surgical excision in Spain [36].
We also would like to highlight here that the patient 
responded well to terbinafine treatment, despite the 
Fig. 3 Distribution of subcutaneous Scedosporium infections in Europe since 1990
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relatively high in  vitro MIC of the drug. A similar phe-
nomenon was observed by Cunningham and Mitchell 
[24] in case of amphotericin B. These findings underline 
the need to handle with care the in vitro antifungal sus-
ceptibility data in the clinical treatment of filamentous 
fungi.
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